RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 Denosumab May Warrant Further Testing in Patients Receiving Long-Term GC Therapy
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 17
SP 19
OP 20
DO 10.1177/155989771417011
UL http://mdc.sagepub.com/content/14/17/19.abstract
AB Although glucocorticoids (GCs) are a backbone of the treatment of rheumatic diseases, they are the major cause of secondary osteoporosis and are associated with increased fracture rate and decreased bone quality. This article discusses outcomes from Denosumab in Current Users of Bisphosphonates for Glucocorticoid-Induced Osteoporosis [NCT01465568].